Design, Synthesis, and Biological Evaluation of Novel Morpholine–Coumarin Derivatives for Inflammation-Associated Depression
Biomolecules · 09.07.2026 · 16 (7) · 1002
DOI: 10.3390/biom16071002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 09.07.2026. Verfasst von Hui Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Natural Medicines of the Changbai Mountain, Yanbian University, Ministry of Education, Yanji 133002, China. Hauptthemen laut MEDLINE: Coumarins, Depression, Inflammation, Morpholines. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research Project of the Science and Technology Department of Jilin Province, Department of Science and Technology of Shandong Province, Natural Science Foundation of Shandong.
Themen: Depression
Abstract (Originalsprache)
The tryptophan–kynurenine pathway, mediated by indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO), is critically involved in the pathogenesis of depression. A series of novel morpholine–coumarin derivatives were designed and synthesized as dual IDO1/TDO inhibitors. Through in vitro enzyme screening, compound 14d exhibited potent inhibitory activity with IC50 values of 0.34 µM and 0.75 µM, respectively. In lipopolysaccharide (LPS)-stimulated BV2 microglial cells, 14d downregulated IDO1/TDO expression, suppressed pro-inflammatory cytokines (IL-1β, COX-2, iNOS, TNF-α), and upregulated the anti-inflammatory cytokine IL-10. In an LPS-induced acute depressive mouse model established in C57BL/6 mice, intraperitoneal administration of 14d (20 mg/kg) significantly reduced immobility time in the forced swim and tail suspension tests, without affecting spontaneous locomotor activity. Mechanistic studies revealed that 14d inhibited microglial activation in the hippocampal dentate gyrus, reduced cerebral kynurenine levels, increased serotonin content, and upregulated BDNF/PKA signaling. Molecular docking further predicted the binding interactions of 14d with the active sites of IDO1 and TDO. These findings suggest that 14d represents a promising dual IDO1/TDO inhibitor lead compound for the treatment of inflammation-associated depression through modulation of the kynurenine pathway and neuroinflammatory responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Natural Medicines of the Changbai Mountain, Yanbian University, Ministry of Education, Yanji 133002, China.
- State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, School of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng 252059, China.
- School of Medicine, Foshan University, Foshan 528000, China.
Förderung
- Key Research Project of the Science and Technology Department of Jilin Province
- Department of Science and Technology of Shandong Province
- Natural Science Foundation of Shandong
Zitieren
APA
Liu, H., Hu, L., Wang, Y., Quan, Z., Liu, Z., Wang, S., & Shen, Q. (2026). Design, Synthesis, and Biological Evaluation of Novel Morpholine–Coumarin Derivatives for Inflammation-Associated Depression. Biomolecules, 16(7), 1002. https://doi.org/10.3390/biom16071002
Vancouver
Liu H, Hu L, Wang Y, Quan Z, Liu Z, Wang S, et al. Design, Synthesis, and Biological Evaluation of Novel Morpholine–Coumarin Derivatives for Inflammation-Associated Depression. Biomolecules. 2026;16(7):1002. doi:10.3390/biom16071002
BibTeX
@article{Liu2026,
author = {Liu, Hui and Hu, Lina and Wang, Yalan and Quan, Zheshan and Liu, Zheng and Wang, Shiben and Shen, Qingkun},
title = {Design, Synthesis, and Biological Evaluation of Novel Morpholine–Coumarin Derivatives for Inflammation-Associated Depression},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {7},
pages = {1002},
doi = {10.3390/biom16071002}
}
EUVIMED